• Loading metrics

Texas and Mexico: Sharing a Legacy of Poverty and Neglected Tropical Diseases

  • Peter J. Hotez ,

    Affiliation Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Section of Pediatric Tropical Medicine, Departments of Pediatrics and Molecular Virology & Microbiology, and National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America

  • Maria Elena Bottazzi,

    Affiliation Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Section of Pediatric Tropical Medicine, Departments of Pediatrics and Molecular Virology & Microbiology, and National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America

  • Eric Dumonteil,

    Affiliation Laboratorio de Parasitología, Centro De Investigaciones Regional “Dr. Hideo Noguchi”, Autonomous University of Yucatan (UADY), Merida, Mexico

  • Jesus G. Valenzuela,

    Affiliation Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

  • Shaden Kamhawi,

    Affiliation Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America

  • Jaime Ortega,

    Affiliation Departamento de Biotecnología y Bioingeniería, Centro de Investigación y de Estudios Avanzados - Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City, Mexico

  • Samuel Ponce de Leon Rosales,

    Affiliation Laboratorios de Biológicos y Reactivos de Mexico (BIRMEX), Mexico City, Mexico

  • Miguel Betancourt Cravioto,

    Affiliation Instituto Carlos Slim de la Salud (ICSS), Mexico City, Mexico

  • Roberto Tapia-Conyer

    Affiliation Instituto Carlos Slim de la Salud (ICSS), Mexico City, Mexico

Texas and Mexico: Sharing a Legacy of Poverty and Neglected Tropical Diseases

  • Peter J. Hotez, 
  • Maria Elena Bottazzi, 
  • Eric Dumonteil, 
  • Jesus G. Valenzuela, 
  • Shaden Kamhawi, 
  • Jaime Ortega, 
  • Samuel Ponce de Leon Rosales, 
  • Miguel Betancourt Cravioto, 
  • Roberto Tapia-Conyer

A consortium of institutions from Texas and Mexico has launched a new initiative for developing vaccines and other tools to control and eliminate neglected tropical diseases in Mesoamerica.

The southern United States and northern Mexico not only share a border, they also share history, culture, and language. With its constant exchange of people and goods, the US–Mexico border region (of which Texas represents a large proportion) can be considered a single, unique, epidemiological unit with its own difficulties and challenges. Although Mexico and Texas have benefited from widespread economic development and with it improvements in life expectancy and overall public health, many diseases in a group of infections known as the neglected tropical diseases (NTDs) still remain highly endemic on both sides of the Texas–Mexico border. The NTDs are the most common infections of the poorest 120 million people in the Americas who live on less than US$2 per day [1]. They include ancient scourges such as hookworm and other soil-transmitted helminth infections, Chagas disease, amoebiasis, schistosomiasis, vivax malaria, leishmaniasis, and dengue [1]. Together, these NTDs produce a burden of disease in the western hemisphere that in certain regions even exceeds HIV/AIDS [1], while simultaneously trapping Latin America's “bottom 100 million” in poverty through their deleterious effects on child physical and intellectual development, pregnancy outcome, and worker productivity [2].

With the exception of schistosomiasis and lymphatic filariasis, most of the major NTDs found in Latin America are also endemic to Mexico [3] (Table 1). Because poverty is an overwhelming risk factor for exposure to NTDs, the estimated 52 million people (46% of the population) who live on less than 2,114 pesos (about US$180) per month in urban areas or 1,329 pesos in rural areas and who lack at least one basic social right suffer the highest rates of these infections. The estimated 11 million people (10% of the population) who live in extreme poverty (less than 978 pesos in urban areas, less than 684 pesos in rural areas) and lacking at least one social right [3] are especially vulnerable [4]. Most of the NTDs occur in Mexico's poorest states, led by the contiguous southern states of Chiapas, Guerrero, and Oaxaca [4]. Overall, these three southern states, in addition to neighboring Campeche, Quintana Roo, Veracruz, and Yucatan, exhibit the lowest human development indices in Mexico [5] (Figure 1). Soil-transmitted helminth infections are among the most common NTDs in Mexico, led by trichuriasis (18 million cases), ascariasis (9 million cases), hookworm infection (1 million cases), and toxocariasis (number of cases not determined) [1], [6]. In rural Chiapas, Necator americanus hookworm infection is a significant cause of maternal-child anemia [7]. In addition, the incidence of cysticercosis, a soil-transmitted platyhelminth infection and a leading cause of epilepsy in Mexico, has been estimated at 0.4 per 100,000 people, with most of the cases in the southern states [5].

Table 1. The major NTDs of the Latin American and Caribbean region, Mexico, and Texas.

Equally important to Mexico are the major vector-borne NTDs, led by up to six million or more cases of Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi), which are found primarily in the states of Chiapas, Oaxaca, Puebla, Veracruz, and Yucatan [8]. In addition to transmission by triatomine kissing bugs, both congenital infections and transfusion-related T. cruzi infections also occur [9]. Leishmaniasis is also endemic. Cutaneous leishmaniasis (CL) is responsible for 99% of the cases, mostly caused by Leishmania mexicana [5]. CL is hyperendemic in the state of Tabasco in association with the cocoa industry there. There are five possible vector species of the genus Lutzomyia responsible for the transmission of CL; Lutzomyia olmeca is the predominant species on the Yucatan peninsula and the incriminated vector in the state of Tabasco for CL [10]. Visceral leishmaniasis has also been reported annually from Chiapas for almost the last 20 years [5]. Unfortunately, most leishmaniasis cases are still underreported in Mexico. Vivax malaria is found predominantly in the poorest states of Chiapas and Oaxaca, as well as in Sinaloa, Chihuahua, Durango, and Tabasco, although only a small percentage of these cases are reported [3], [5]. Fewer than 3,000 cases of vivax malaria were reported in Mexico in 2005 and 2009 (and less than 1,000 cases in 2011) [5]. Onchocerciasis is traditionally endemic in three distinct foci in Mexico, i.e., Oaxaca, northern Chiapas, and southern Chiapas [11], [12], although in 2010 it was reported that no transmission has been detected in the first two foci [11], [12]. Dengue remains highly endemic in Mexico [13], with dengue virus type 2 (DENV-2) representing the predominant serotype [5]. However, all four serotypes of dengue are now present in Mexico, due to reintroduction of DENV-1 and DENV-4 from Central America, and rates of severe dengue have increased significantly since 2000 [5]. West Nile virus infection has also been reported in Mexico [5].

Among the protozoan NTDs, amoebiasis and giardiasis are each widespread enteric infections [14], [15], and toxoplasmosis is an important protozoan infection and a risk for pregnant women [16], although national prevalence data are not available for any of these conditions. Brucellosis, leprosy, leptospirosis, and trachoma are the major bacterial NTDs [3]. The incidence of human brucellosis is two to three cases per 100,000 people, with the largest number in the states of Coahuila, Nuevo Leon, Sinaloa, and Zacatecas, mostly from contaminated milk and milk products [5]. Mexico is one of three Latin American countries (the others being Brazil and Guatemala) with endemic trachoma [17]. The disease is endemic in five municipalities of Los Altos-Chiapas, with a control program in place to search for cases house by house [5]. The World Health Organization reported 478 cases of registered leprosy in Mexico at the end of the first quarter of 2011 [18]. Canine rabies is still reported in Mexico, with two deaths from dog bites between 2000 and 2005 [5]. Overall, there is a need to increase our understanding of the epidemiology for NTDs in Mexico.

Across the border, the state of Texas is neither immune to poverty nor to the NTDs. Indeed, at a 17% poverty rate, Texas has a significantly higher rate than the overall 14% poverty rate in the United States [19]. With 4.15 million people living below the poverty line, Texas may have the largest number of poor people of any state in the US [19]. The poverty rates are highest among Hispanic (26%) and African-American minorities (23%) and among children under the age of five (all races) (28%) [19]. Poverty in Texas is concentrated in South Texas, especially along the border with Mexico (Figure 2).

Figure 2.

Figure created at with data from US Census Bureau 2010 Small Area Income and Poverty Estimates accessed at March 6, 2012.

Emerging evidence over the last few years has revealed a hidden burden of NTDs and related neglected infections of poverty in Texas [20]. Among the helminthic NTDs during the first half of the 20th century, hookworm infection was hyperendemic in east Texas [21][23], with prevalence rates as high as 84% in the Piney Woods counties of Sabine, San Augustine, Jasper, and Newton [21]. The infection was found in association with sandy soils present near rivers [21]. Hymenolepiasis was also determined to be widespread during this period [21]. However, no studies of hookworm in Texas have been reported in the last 50 years, and it is not known whether hookworm or other intestinal helminth infections such as ascariasis and trichuriasis remain endemic in the poorest rural areas of east Texas. In contrast, it is now well established that cysticercosis is a leading cause of epilepsy among Hispanics living in Texas [24], [25]. Up to 169,000 cases of cysticercosis are estimated to occur in the US, with Texas and California most likely representing the greatest share of the disease burden from this condition [20]. Toxocariasis, a zoonotic larval helminth infection, is widespread among African-American and Hispanic populations in the American South [20]; based on its prevalence among urban dogs in Houston and presumably elsewhere [26], it is likely that toxocariasis is also widespread in Texas. This condition has been linked to asthma and developmental delays [27].

Several important vector-borne NTDs have recently emerged in Texas, led by Chagas disease, leishmaniasis, and dengue [20]. Up to 267,000 cases of Chagas disease are believed to occur in Texas [28], although this figure may be an overestimate [29]. The largest number of US cases of Chagas disease may occur in Texas as a result of human migrations from Mexico in addition to autochthonous transmission [30], [31]. Infected vectors or hosts are present in 82 of the 254 counties of Texas [30]; they include wild zoonotic reservoirs such as armadillos, coyotes, raccoons, opossums, and rodents of the genus Neotoma, canine reservoirs, and up to 11 species of kissing bugs, including three major Triatoma species, i.e., Triatoma gerstaeckeri, Triatoma sanguisuga, and Triatoma leticulara [30], [31]. Two major genotypes of T. cruzi, i.e., TcI and TcIV, have been reported from the US [31]. Although only four cases of autochthonous infections have been recorded in Texas [31], this number is likely to be an underestimate of the true number of cases [32], with the additional possibility of congenital infections [9], [31], [33]. A risk analysis based on the ecology and incidence of T. cruzi infection among vectors and animal reservoirs indicates that the greatest risk of Chagas disease occurs in the south Texas counties of Cameron, Nueces, Kleberg, Hidalgo, Jim Wells, Willacy, Medina, Dimmit, Frio, and Bandera, with expectations of T. cruzi exposures and infections among the major population centers in Dallas, Houston, and San Antonio [30]. CL from L. mexicana infection (which is transmitted by Lutzomyia sand flies) is endemic in south-central Texas [34], [35], with at least nine autochthonous cases reported from north Texas [36]. The suspected (but unproven) vector for CL in this area is Lutzomyia diabolica, but more entomological and parasitological studies are required to define the sand fly vector species responsible for the transmission of CL. Dengue is also endemic along the border with Mexico, with an estimated 2% seroprevalence in Brownsville [37]. The major risk factors along the Texas–Mexico border include low weekly family income, absence of air conditioning and window screens, and inadequate sanitation [37], [38]. Such conditions are found more commonly across the border from Brownsville in Matamoros, Tamaulipas State, Mexico, where the seroprevalence is almost four times higher [37]. Of particular concern is the observation that a more virulent and transmissible genotype of dengue serotype 2 has been introduced into the Texas–Mexico border area [39]. Approximately 100,000–200,000 cases of dengue have been estimated to occur among the Mexican-American population in the US [20].

The high prevalence and incidence of the major NTDs in both Mexico and south Texas afford an opportunity for joint cooperation to address the highest prevalence conditions, especially Chagas disease, CL, dengue, and the soil-transmitted helminth infections. For each of these NTDs there are widely disparate disease estimates available, and this situation suggests some urgency for programs of active surveillance based on seroprevalence and other diagnostics studies. There is an equally urgent need to determine the major mechanisms of transmission, which for Chagas disease would also include the transmission from dogs and other canines, estimates of the extent of congenital infection, and the incidence of infection acquired through blood transfusion. Such efforts should include studies to screen for congenital Chagas disease transmission in hospitals with a high proportion of women from Latin America [31]. Among the recommendations recently suggested for the control of Chagas disease in Texas is the need to make Chagas disease reportable (as it has been in Arizona and Massachusetts [30]), to carry out serological studies of human and canine populations, to monitor the extent of T. cruzi infection in rodents and other wild zoonotic reservoirs, and to undertake widespread testing of blood donors and other at-risk populations [30]. Similar programs of surveillance and transmission dynamics are also required for CL, dengue, and helminth infections [20]. Given the risks of Chagas disease (including congenital Chagas disease) in Mexico and the US, there is an urgent need to educate cardiologists, obstetricians, and other health care providers about the likelihood of this and other neglected infections of poverty [31].

There is also an urgent need to develop alternative control tools for the major NTDs. Recently, the Instituto Carlos Slim de la Salud (Carlos Slim Health Institute) launched a joint US–Mexico initiative to develop NTD vaccines, beginning with Chagas disease and CL [2], [40]. The Iniciativa Slim para el desarollo de vacunas contra enfermedades tropicales (Slim Initiative for developing tropical disease vaccines) is focusing its initial efforts on developing a therapeutic vaccine for Chagas disease with an emphasis on two recombinant T. cruzi antigens, Tc24 and TSA-1 [2], [41], and a preventative CL vaccine against L. mexicana infection comprised of a recombinant L. mexicana nucleoside hydrolase [42][44] and a recombinant Lutzomyia sand fly salivary antigen [45][47]. Such antigens would be developed jointly by institutions based in Texas and Mexico, in addition to the US National Institutes of Health, with manufacture under cGMPs (current good manufacturing practices) by Laboratorios de Biológicos y Reactivos de Mexico (Birmex) [48], the major biologics manufacturing organization of the Mexican government.

In parallel, a newly established Section of Pediatric Tropical Medicine at Texas Children's Hospital of Baylor College of Medicine has linked with other institutions within the Texas Medical Center and the Sabin Vaccine Institute to develop vaccines and other appropriate technologies for NTDs [49], [50]. These organizations provide the basis for a new National School of Tropical Medicine recently established at Baylor College of Medicine [51], [52]. Under the auspices of the Slim Initiative, it is anticipated that these joint activities might lead to a new generation of NTD vaccines for hookworm, Chagas disease, and leishmaniasis. Such technologies are sometimes referred to as “antipoverty vaccines” for their potential impact to not only improve health, but also to help lift Latin America's bottom 100 million out of poverty [53], [54]. Ultimately, an all-out assault on the NTDs is necessary if we hope to achieve elimination of these ancient conditions in the coming decade.


  1. 1. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Roses Periago M (2008) The neglected tropical diseases of Latin America and the Caribbean: review of estimated disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e300. doi:10.1371/journal.pntd.0000300.
  2. 2. Hotez PJ, Dumonteil E, Heffernan MJ, Bottazzi MD (2012) Innovation for “the bottom 100 million”: eliminating neglected tropical diseases in the Americas through mass drug administration and new vaccines for hookworm and Chagas disease. Adv Exp Med Biol. In press.
  3. 3. Bottazzi ME, Dumonteil E, Valenzuela J, Betancourt-Cravioto M, Tapia-Conyer R, et al. (2011) Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines. Boletin Medico de Hospital Infantil de Mexico 68: 130.
  4. 4. (6 September 2011) Is poverty in Mexico on the rise? Available: Accessed 2 March 2012.
  5. 5. Pan American Health Organization (World Health Organization) (2007) Health in the Americas 2007. Volume I - regional; Volume II - counties. Scientific and technical publication no. 622.
  6. 6. Por MA, Munoz-Guzman BE, del Rio-Navarro G, Valdivia-Anda F, Alba-Hurtado (2010) The increase in seroprevalence to Toxocara canis in asthmatic children is related to cross-reaction with Ascaris sum antigens. Allergologia et Immunopathologia 38:
  7. 7. Brentlinger PE, Capps L, Denson M (2003) Hookworm infection and anemia in adult women in rural Chiapas, Mexico. Salud Publica Mex 117–119.
  8. 8. Cruz-Reyes A, Pickering-Lopez JM (2006) Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years – a review. Mem Inst Oswaldo Cruz, Rio de Janeiro 101: 345–354.
  9. 9. Buekens P, Almendares O, Carlier Y, Dumonteil E, Eberhard M, et al. (2008) Mother-to-child transmission of Chagas disease in North America: why don't we do more? Matern Child Health J 12: 283–286.
  10. 10. Pech-May A, Escobedo-Ortegon FJ, Berzunza-Cruz M, Rebollar-Tellez EA (2010) Incrimination of four sandfly species previously unrecognized as vectors of Leishmanias parasites in Mexico. Med Vet Entomol 24: 150–161.
  11. 11. Rodriguez-Perez MA, Unnasch TR, Dominguez-Vazquez A, Morales-Castro AL, Pena-Flores GP, et al. (2010) Interruption of transmission of Onchocerca volvulus in the Oaxaca focus, Mexico. Am J Trop Med Hyg 83: 21–27.
  12. 12. Rodriguez-Perez MA, Unnasch TR, Dominguez-Vazuez A, Morales-Castro AL, Richards F Jr (2010) Lack of active Onchocerca volvulus transmission in the northern Chiapas focus of Mexico. Am J Trop Med Hyg 83: 15–20.
  13. 13. Gomez-Dantes H, Willoquet JR (2009) Dengue in the Americas: challenges for prevention and control. Cad. Saude Publica, Rio de Janeiro 25 Sup 1S19–S31.
  14. 14. Ximenez C, Moran P, Rojas L, Valadez A, Gomez A, et al. (2011) Novelties on amoebiasis: a neglected tropical disease. J Glob Infect Dis 3: 166–174.
  15. 15. Cedillo-Rivera R, Leal YA, Yépez-Mulia L, Gómez-Delgado A, Ortega-Pierres G, et al. (2009) Seroepidemiology of giardiasis in Mexico. Am J Trop Med Hyg 80: 6–10.
  16. 16. Alvarado-Esquivel C, Torres-Castorena A, Liesenfeld O, García-López CR, Estrada-Martínez S, et al. (2009) Seroepidemiology of Toxoplasma gondii infection in pregnant women in rural Durango, Mexico. J Parasitol 95: 271–274.
  17. 17. World Health Organization (n.d.) WHO global health atlas. Available: Accessed 2 March 2012.
  18. 18. World Health Organization (2011) Leprosy update, 2011. Weekly Epidemiol Record 86: 389–400.
  19. 19. Center for Public Policy Priorities (2010) Poverty 101. Available: Accessed 2 March 2012.
  20. 20. Hotez PJ (2008) Neglected infections of poverty in the United States of America. PLoS Negl Trop Dis 2: e256. doi:10.1371/journal.pntd.0000256.
  21. 21. Upton RG (1936) Incidence and severity of hookworm infestation in East Texas. Am J Public Health Nations Health 26: 924–926.
  22. 22. Scott JA (1945) Hookworm disease in Texas. Texas Rep Biol Med 3: 558–568.
  23. 23. Henderson HE (1957) Incidence and intensity of hookworm infestation in certain East Texas counties with comparison of technics. Texas Rep Biol Med 15: 283–291.
  24. 24. Shandera WX, White AC Jr, Chen JC, Diaz P, Armstrong R (1994) Neurocysticercosis in Houston, Texas. A report of 112 cases. Medicine (Baltimore) 73: 37–52.
  25. 25. White AC Jr, Atmar RI (2002) Infections in Hispanic immigrants. Clin Infect Dis 34: 1627–1632.
  26. 26. Arambulo PV 3rd, Steele JH (1976) Urban dogs in Houston, Texas – parasitic infection and environmental health impact. Int J Zoonoses 3: 114–144.
  27. 27. Hotez PJ, Wilkins P (2009) Toxocariasis: America's most common neglected infection of poverty and a helminthiasis of global importance? PLoS Negl Trop Dis 3: e400. doi:10.1371/journal.pntd.0000400.
  28. 28. Hanford EJ, Zhan FB, Lu Y, Giordano A (2007) Chagas disease in Texas: recognizing the significance and implications of evidence in the literature. Soc Sci Med 65: 60–79.
  29. 29. Bern C, Montgomery SP (2009) An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52–e54.
  30. 30. Sarkar S, Strutz SE, Frank DM, Rivaldi C-L, Sissel B, et al. (2010) Chagas disease risk in Texas. PLoS Negl Trop Dis 4: e836. doi:10.1371/journal.pntd.0000836.
  31. 31. Bern C, Kjos S, Yabsley MJ, Montgomery SP (2011) Trypanosoma cruzi and Chagas' disease in the United States. Clin Microbiol Rev 24: 655–681.
  32. 32. Beard CB, Pye G, Steurer FJ, Rodriguez R, Campman R, et al. (2003) Chagas disease in a domestic transmission cycle in southern Texas, USA. Emerg Infect Dis 9: 103–105.
  33. 33. Bowling J, Walter EA (2009) Recognizing and meeting the challenge of Chagas disease in the USA. Expert Rev Anti Infect Ther 7: 1223–1234.
  34. 34. Enserink M (2000) Infectious diseases. Has leishmaniasis become endemic in the U.S.? Science 290: 1881–1883.
  35. 35. McHugh CP (2010) Cutaneous leishmaniasis in Texas. J Am Acad Dermatol 62: 508–510.
  36. 36. Wright NA, David LE, Aftergut KS, Parrish CA, Cockerell CJ (2008) Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol 58: 650–652.
  37. 37. Brunkard JM, Robles Lopez JL, Ramirez J, Cifuentes E, Rothenberg SJ, et al. (2007) Dengue fever seroprevalence and risk factors, Texas-Mexico border, 2004. Emerg Infect Dis 13: 1477–1483.
  38. 38. Reiter P, Lathrop S, Bunning M, Biggerstaff B, Singer D, et al. (2003) Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis 9: 86–89.
  39. 39. Rico-Hesse R (2007) Dengue virus evolution and virulence models. Clin Infect Dis 44: 1462–1466.
  40. 40. Instituto Carlos Slim de la Salud (2010) Iniciativa Slim para el Desarrollo de Vacunas contra Enfermedades Tropicales. Available: Accessed 2 March 2012.
  41. 41. Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sánchez-Burgos G, et al. (2010) Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ cells. Vaccine 28: 7414–7419.
  42. 42. Chale-Balboa WG, Mut-Martin M, Ramirez-Sierra MJ, Garcia-Miss MR, Dumonteil E (2009) A combination of DNA vaccine encoding nucleoside hydrolase 36 and glycoprotein 63 protects female but not male hamsters against Leishmania mexicana. Parasite 16: 227–230.
  43. 43. Dumonteil E (2009) Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 9: 1075–1082.
  44. 44. Herrera-Najera C, Pina-Aguilar R, Xacur-Garcia F, Ramirez-Sierra MJ, Dumonteil E (2009) Mining the Leishmania genome for novel antigens and vaccine candidates. Proteomics 9: 1293–1301.
  45. 45. Collin N, Gomes R, Teixeira C, Cheng L, et al. (2009) Sand fly proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog 5: e1000441. doi:10.1371/journal.ppat.1000441.
  46. 46. Gomes R, Teixeira C, Teixera MJ, Oliveira F, Menezes MJ, et al. (2008) Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A 105: 7845–7850.
  47. 47. Oliveria F, Lawyer PG, Kamhawi S, Valenzuela JG (2008) Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl Trop Dis 2: e226. doi:10.1371/journal.pntd.0000226.
  48. 48. Birmex (n.d.) Birmex website. Available: Accessed 2 March 2012.
  49. 49. Hotez PJ (2008) Training the next generation of global health scientists: a school of appropriate technology for global health. PLoS Negl Trop Dis 2: e279. doi:10.1371/journal.pntd.0000279.
  50. 50. Hotez P (2010) A national school of tropical medicine and neglected infections of poverty in North America. PLoS Negl Trop Dis 4: e735. doi:10.1371/journal.pntd.0000735.
  51. 51. Baylor College of Medicine (n.d.) National School of Tropical Medicine website. Available: Accessed 2 March 2012.
  52. 52. Hotez P (27 October 2011) Neglected tropical diseases deserve attention [opinion]. Austin Statesman.
  53. 53. Hotez PJ, Ferris M (2006) The antipoverty vaccines. Vaccine 24: 5787–5799.
  54. 54. Hotez P (2011) A handful of ‘antipoverty’ vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood) 30: 1080–1087.